First Tracks Biotherapeutics (TRAX) FDA Approvals $31.85 0.00 (0.00%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$31.88 +0.02 (+0.08%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest First Tracks Biotherapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by First Tracks Biotherapeutics (TRAX). Over the past two years, First Tracks Biotherapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ANB033. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ANB033 FDA Regulatory Events ANB033 is a drug developed by First Tracks Biotherapeutics for the following indication: in Celiac Disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 11,2026Provided Update Drug: ANB033Announced Date: October 11, 2026Indication: in Celiac DiseaseAnnouncementFirst Tracks Biotherapeutics, Inc. will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.Read Announcement First Tracks Biotherapeutics FDA Events - Frequently Asked Questions Has First Tracks Biotherapeutics received FDA approval? As of now, First Tracks Biotherapeutics (TRAX) has not received any FDA approvals for its therapy in the last two years. What drugs has First Tracks Biotherapeutics submitted to the FDA? In the past two years, First Tracks Biotherapeutics (TRAX) has reported FDA regulatory activity for ANB033. What is the most recent FDA event for First Tracks Biotherapeutics? The most recent FDA-related event for First Tracks Biotherapeutics occurred on October 11, 2026, involving ANB033. The update was categorized as "Provided Update," with the company reporting: "First Tracks Biotherapeutics, Inc. will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT." What conditions do First Tracks Biotherapeutics' current drugs treat? Currently, First Tracks Biotherapeutics has one therapy (ANB033) targeting the following condition: in Celiac Disease. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events BridgeBio Pharma FDA EventsMirum Pharmaceuticals FDA EventsFirst Tracks Biotherapeutics FDA EventsAbbVie FDA EventsLB Pharmaceuticals FDA EventsMerck & Co., Inc. FDA EventsAlumis FDA EventsArcutis Biotherapeutics FDA EventsBioMarin Pharmaceutical FDA EventsHCW Biologics FDA EventsMilestone Pharmaceuticals FDA EventsPureTech Health FDA EventsGlaukos FDA EventsJohnson & Johnson FDA EventsEli Lilly and Company FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Edgewise Therapeutics FDA Events Relay Therapeutics FDA Events Tango Therapeutics FDA Events AbCellera Biologics FDA Events Legend Biotech FDA Events Veracyte FDA Events Viking Therapeutics FDA Events Xenon Pharmaceuticals FDA Events ACADIA Pharmaceuticals FDA Events Celcuity FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:TRAX last updated on 10/12/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Tracks Biotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share First Tracks Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 11,2026Provided Update Drug: ANB033Announced Date: October 11, 2026Indication: in Celiac DiseaseAnnouncementFirst Tracks Biotherapeutics, Inc. will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT.Read Announcement
